var data={"title":"Mepivacaine and levonordefrin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mepivacaine and levonordefrin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6534?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mepivacaine-and-levonordefrin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mepivacaine and levonordefrin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193034\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Carbocaine 2% with Neo-Cobefrin;</li>\n      <li>Polocaine Dental;</li>\n      <li>Scandonest 2% L</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193035\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Carbocaine 2% with Neo-Cobefrin;</li>\n      <li>Scandonest 2% with Levonordefrin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193042\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193036\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. Always use the lowest effective dose along with careful aspiration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Dental anesthesia, infiltration, or conduction block:</b> Usual dose: Mepivacaine 34 mg (1.7 mL) per site or mepivacaine 180 mg (9 mL) for entire oral cavity; maximum cumulative <b>mepivacaine</b> dose: 6.6 mg/kg or 400 mg (whichever is less) during any single dental sitting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193038\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. Always use the lowest effective dose along with careful aspiration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dental anesthesia, infiltration, or conduction block:</b> Children and Adolescents: Maximum dosage must be carefully calculated on the basis of patient's weight. Manufacturer recommends a maximum mepivacaine dose of 6.6 mg/kg, but must not exceed 180 mg as a 2% solution. The American Academy of Pediatric Dentistry (AAPD) recommends a maximum mepivacaine dose of 4.4 mg/kg or a maximum total dose of 300 mg in any single dental sitting (AAPD 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193037\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; reduce dose consistent with age and physical status.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570286\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570287\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193025\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [for dental use]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carbocaine 2% with Neo-Cobefrin: Mepivacaine hydrochloride 2% and levonordefrin 1:20,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Scandonest 2% L: Mepivacaine hydrochloride 2% and levonordefrin 1:20,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193014\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14723454\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer slowly, with frequent aspirations before and during the injection to avoid intravascular injection. Use with caution when there is inflammation and/or sepsis in the region of the proposed injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15162767\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dental anesthesia: </b>Production of local anesthesia for dental procedures by infiltration or nerve block in adult and pediatric patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193021\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of mepivacaine. The effects below are more likely to occur after systemic administration rather than infiltration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Disorientation, dizziness, drowsiness, excitement, loss of consciousness, nervousness, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, oral paresthesia (lips, oral tissues, and tongue; usually due to nerve blocks of the trigeminal nerve)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193028\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mepivacaine, levonordefrin, local anesthetics of the amide-type, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193018\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, hypertension, and ischemic heart disease; minimal amounts of vasoconstrictor should be used in this patient population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill patients: Use with caution in acutely ill patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Potassium metabisulfite: Some preparations may contain potassium metabisulfite which may cause severe hypersensitivity reactions (anaphylaxis) in some individuals; use caution in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Use with caution when there is inflammation and/or sepsis in the region of the proposed injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate dosing: To avoid serious adverse effects and high plasma levels, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may cause significant increases in blood levels with each repeated dose due to the possibility of accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with patient status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Dental practitioners using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299670\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193022\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10138&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Levonordefrin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193023\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287254\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193030\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if mepivacaine or levonordefrin is present in breast milk. The manufacturer recommends that caution be exercised when administering mepivacaine/levonordefrin to breastfeeding women. Usual infiltration doses of mepivacaine with levonordefrin given to breastfeeding mothers has not been shown to affect the health of the breastfed infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193017\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levonordefrin: Prolongs the duration of the anesthetic actions of mepivacaine by causing vasoconstriction (alpha-adrenergic receptor agonist) of the vasculature surrounding the nerve axons. This prevents the diffusion of mepivacaine away from the nerves resulting in a longer retention in the axon.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193027\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Upper jaw: 30 to 120 seconds; Lower jaw: 1 to 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Upper jaw: 1 to 2.5 hours; Lower jaw: 2.5 to 5.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Mepivacaine: ~75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Mepivacaine: Primarily hepatic via N-demethylation, hydroxylation, and glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Mepivacaine: Urine (90% to 95% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193031\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Polocaine 2% and Levonordefrin 1:20,000 (CA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Association of Pediatric Dentists (AAPD), Council on Clinical Affairs. Guideline on use of local anesthesia for pediatric dental patients. 2009. Available at http://www.aapd.org/media/Policies_Guidelines/G_LocalAnesthesia.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Association of Pediatric Dentists (AAPD), Council on Clinical Affairs. Guideline on use of local anesthesia for pediatric dental patients. Revised 2015. Available at http://www.aapd.org/media/Policies_Guidelines/G_LocalAnesthesia.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ayoub ST and Coleman AE, &ldquo;A Review of Local Anesthetics,&rdquo; <i>Gen Dent</i>, 1992, 40(4):285-7, 289-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/1397990/pubmed\" target=\"_blank\" id=\"1397990\">1397990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carbocaine with Neo-Cobefrin (mepivacaine and levonordefrin) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canda, Inc; June 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/1397990/pubmed\" target=\"_blank\" id=\"1397990\">1397990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaffen AS and Haas DA, &quot;Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,&quot; <i>J Can Dent Assoc</i>, 2009, 75(8):579.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/19840499/pubmed\" target=\"_blank\" id=\"19840499\">19840499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garisto GA, Gaffen AS, Lawrence HP, et al, &quot;Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,&quot; <i>J Am Dent Assoc</i>, 2010, 141(7):836-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/20592403/pubmed\" target=\"_blank\" id=\"20592403\">20592403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo; <i>J Am Dent Assoc</i>, 1983, 107(4):623-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/6355236/pubmed\" target=\"_blank\" id=\"6355236\">6355236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacKenzie TA and Young ER, &ldquo;Local Anesthetic Update,&rdquo; <i>Anesth Prog</i>, 1993, 40(2):29-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/8185087/pubmed\" target=\"_blank\" id=\"8185087\">8185087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polocaine Dental (mepivacaine and levonordefrin) [prescribing information]. Cambridge, Ontario, Canada: Dentsply Pharmaceutical; March 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scandonest L (mepivacaine and levonordefrin) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canda, Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24428507\"></a>Su N, Liu Y, Yang X, Shi Z, Huang Y. Efficacy and safety of mepivacaine compared with lidocaine in local anaesthesia in dentistry: a meta-analysis of randomised controlled trials. <i>Int Dent J</i>. 2014;64(2):96-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/24428507/pubmed\" target=\"_blank\" id=\"24428507\">24428507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo; <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/7911769/pubmed\" target=\"_blank\" id=\"7911769\">7911769</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Recent Research on Mechanisms of Local Anesthetics,&rdquo; <i>Gen Dent</i>, 1995, 43(4):316-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/8940589/pubmed\" target=\"_blank\" id=\"8940589\">8940589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yagiela JA, &ldquo;Local Anesthetics,&rdquo; <i>Anesth Prog</i>, 1991, 38(4-5):128-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mepivacaine-and-levonordefrin-drug-information/abstract-text/1819966/pubmed\" target=\"_blank\" id=\"1819966\">1819966</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10138 Version 84.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193034\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193035\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F193042\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F193036\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F193038\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F193037\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16570286\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16570287\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193025\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F193014\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14723454\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15162767\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193021\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193028\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193018\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299670\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193022\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193023\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14287254\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F193030\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193017\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F193027\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193031\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10138|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mepivacaine-and-levonordefrin-patient-drug-information\" class=\"drug drug_patient\">Mepivacaine and levonordefrin: Patient drug information</a></li></ul></div></div>","javascript":null}